# Effectiveness and Safety of EN3835 in the Treatment of EFP (Cellulite) in Women

> **NCT03428750** · PHASE3 · COMPLETED · sponsor: **Endo Pharmaceuticals** · enrollment: 423 (actual)

## Conditions studied

- Edematous Fibrosclerotic Panniculopathy (Cellulite)

## Interventions

- **BIOLOGICAL:** EN3835
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT03428750
- **Lead sponsor:** Endo Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-05
- **Primary completion:** 2018-09-26
- **Final completion:** 2018-09-26
- **Target enrollment:** 423 (ACTUAL)
- **Last updated:** 2020-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03428750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03428750, "Effectiveness and Safety of EN3835 in the Treatment of EFP (Cellulite) in Women". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03428750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*